HiSiaddi is an innovative foreign trade service provider driven by technology transformation and cross-border trading. We have established a "1+2+3+4=1" service system and can supply L-theanine sourced from multiple well-known original manufacturers. As a technology-driven foreign trade enterprise, HiSiaddi has repeatedly collaborated with factories on technology conversion and accurately captured market demands to resolve customized L-theanine product requirements for clients. Below is a case illustrating how HiSiaddi delivered a customized L-theanine solution.
Contact HiSiaddi customer service for more customized service inquiries.
The purchaser is HEALTHLIFE Co., Ltd., headquartered in Osaka, Japan, a leading manufacturer of mid-to-high-end dietary supplements and auxiliary pharmaceutical excipients for prescription drugs in Japan. The company specializes in premium calming health food and hospital formulation raw materials, whose products are distributed via Japanese drugstore chains and public medical institutions. Its product quality control complies with the Japanese Pharmacopoeia (JP), Japan Ministry of Health, Labour and Welfare food additive standards, EU REACH, and US USP specifications. The enterprise has purchased original pharmaceutical-grade L-theanine from Kyowa Hakko for over a decade, with an annual L-theanine procurement volume of 135 tons.
Due to production capacity cuts by overseas original manufacturers, continuous price hikes of raw materials in Japan and South Korea, and extended lead times exceeding 85 days, the client launched a domestic raw material substitution project. Leveraging its self-developed new-generation high-purity sustained-release calming formula, it proposed customized technical specifications for L-theanine beyond national standard commercial grades. The client planned to first customize 18 tons of pharmaceutical-grade tailor-made goods; upon successful lab verification, it would fully switch its annual supply chain to domestic suppliers.
The client independently contacted four leading domestic L-theanine manufacturers (Zhejiang Kangpu, Fujian Huimin Bio, Shandong Heyuan, Jiangsu Lvkang) to discuss customized development, yet the customization project hit a dead end. Mass production lines of domestic manufacturers are designed for national standard food-grade L-theanine, with general commercial food-grade purity ranging from 98.0% to 99.0%. All manufacturers adopt basic enzymatic synthesis and single recrystallization production processes. Restricted by existing refining equipment and purification technology, they can only fine-tune parameters within standard mass production specifications and refuse to revamp deep refining sections for small-batch orders of 18 tons. Multiple batches of national standard spot samples sent by manufacturers to the client’s Japanese R&D center failed testing due to excessive heavy metals, high residual solvents, out-of-spec related substances, and unstable optical rotation, failing to meet Japanese Pharmacopoeia pharmaceutical standards and halting the client’s new formulation R&D production line.
Recommended by the Japan Health Food Industry Association, the Japanese procurement and R&D team entrusted HiSiaddi, which is fully equipped with pharmaceutical raw material R&D engineers and partnered CNAS-certified pharmaceutical pilot lab resources, to deliver one-stop customized services covering formula process optimization, lab sampling, pilot scale-up, mass customized production, and cross-border export compliance.
1. HPLC chromatographic purity ≥99.70% (domestic standard food-grade only requires ≥98.0%);
2. Single unknown related substance ≤0.05%, total impurities ≤0.20%;
3. Specific optical rotation [α]₂₀ᴰ: +7.8° ~ +8.3°, strict narrow range control to avoid excess chiral isomers;
4. Heavy metal limits: Lead <0.5ppm, Arsenic <0.3ppm, Cadmium <0.1ppm, Mercury <0.1ppm, far stricter than national food-grade limits;
5. Residual solvents: Methanol, Ethanol, Isopropanol each <10ppm, total residual solvents ≤25ppm, compliant with Japanese Pharmacopoeia residual substance control;
6. Moisture ≤0.15%, ignition residue ≤0.08%;
7. Microbial control: Total aerobic bacteria <10CFU/g, absence of Salmonella, Escherichia coli, mold and yeast, meeting pharmaceutical sterile feeding standards;
8. Uniform acicular crystal form, particle size 80–150 mesh, no ultrafine dust, compatible with tablet pressing formulation processes.
1. High cost of deep refining process transformation: Conventional domestic production adopts single aqueous recrystallization. To achieve 99.7% ultra-high purity and ultra-low related substances, multi-stage gradient cooling recrystallization and membrane filtration impurity removal sections must be added. Existing crystallizers and separation equipment of most manufacturers cannot support refined purification, and independent technical transformation requires heavy investment, making factories reluctant to revamp production lines solely for small-batch customized orders.
2. Precise control of chiral optical rotation is technically demanding: Trace D-type chiral isomers are easily generated during L-theanine production and cannot be accurately removed via conventional processes. Stabilizing optical rotation within a narrow range requires precise regulation of enzyme activity and reaction temperature during enzymatic catalysis, yet most manufacturers lack online chiral detection for in-process control.
3. High threshold for ppm-level heavy metal and residual solvent fine purification: Raw materials, process water and catalytic additives used in production may introduce heavy metals. Conventional atmospheric drying cannot thoroughly remove organic solvents, requiring ion exchange heavy metal removal devices and continuous low-temperature vacuum drying equipment.
4. Scarce pharmaceutical-grade sterile production environments: Microbial indicators of finished products follow Japanese pharmaceutical raw material standards, requiring closed production in Class D clean workshops for production and packaging. Most domestic food-grade manufacturers lack GMP-certified clean production workshops.
5. Cumbersome supporting compliance documents for multiple pharmacopoeias: Customized products must be accompanied by Japanese JP Pharmacopoeia test reports, USP compliance documents, REACH-SVHC screening, and Japan Ministry of Health import raw material filing documents. Ordinary food raw material manufacturers lack capabilities to compile pharmaceutical compliance materials and conduct designated testing.
HiSiaddi formed a four-person special team consisting of pharmaceutical amino acid R&D engineers, supply chain project specialists, third-party pharmaceutical testing coordinators, and export compliance specialists, closing the full customized development cycle within 31 days.
1. Combining enzymatic synthesis mechanisms, HiSiaddi technical engineers collaborated with GMP clean workshop API manufacturers to optimize production: High-activity immobilized transaminase was selected, substrate feed ratio, reaction pH and constant catalytic temperature were precisely controlled to reduce D-type isomer generation at the source and stabilize optical rotation within the specified range.
2. Abandoning single recrystallization, a water-alcohol dual-solvent three-stage gradient cooling recrystallization plus nanofiltration fine impurity removal process was adopted to gradually strip process byproducts and related impurities. Cation-anion exchange resin columns were matched to deeply adsorb heavy metal ions such as lead and arsenic.
3. Finished products underwent segmented high-vacuum low-temperature gradient drying to layerwise remove residual organic solvents without damaging crystal forms. Crystallization, crushing and sieving were conducted in closed Class D clean environments to precisely control particle size range.
Six groups of optimized formula samples were iteratively produced, each fully tested for pharmacopoeia compliance at a CNAS-certified pharmaceutical lab. The optimal process was finalized with measured HPLC purity of 99.76%, total impurities 0.16%, optical rotation +8.02°, all heavy metals below internal control limits, and total residual solvents 21ppm – all indicators superior to the client’s customized requirements. 5kg sterile vacuum aluminum foil packaged samples were airfreighted to the client’s Osaka lab in Japan.
1. Coordinated the factory to exclusively deploy a dedicated Class D GMP clean production line with full isolation to avoid cross-contamination with food-grade products. Real-time monitoring of temperature, humidity and differential pressure in the clean zone was implemented during production, with key indicators sampled and tested every 3 hours for in-process control.
2. Pilot finished products were simultaneously sent to authoritative third-party institutions for full Japanese JP Pharmacopoeia testing, USP compliance testing and comprehensive microbial screening. Bilingual Japanese-English pharmacopoeia-level COA and TDS physical data sheets were issued.
3. The client conducted small-scale tablet pressing trials for calming formulations: Raw materials exhibited excellent flowability with no sticking during tableting. No precipitation occurred during long-term storage of tablets, and dissolution rates met standards. The complete formula successfully passed formulation stability evaluation by the Japanese pharmaceutical enterprise.
Leveraging HiSiaddi’s long-term strategic upstream API supply resources, the factory was negotiated to utilize monthly spare capacity of the GMP workshop for dedicated production of 18 tons of customized L-theanine on the full refined clean production line. HiSiaddi deployed on-site quality control staff to oversee full production and batch-by-batch sampling inspection. Custom packaging was manufactured in line with Japanese pharmaceutical raw material warehousing standards: inner pharmaceutical vacuum aluminum foil bags, outer 25kg food & pharmaceutical-grade fiber drums, with drums printed with bilingual Japanese-English GHS hazard labels for full light-shielded sealed packaging.
1. Compliance engineers compiled 16-chapter bilingual Japanese-English SDS safety data sheets attached with JP Pharmacopoeia test annexes in accordance with Japan Ministry of Health and EU REACH regulations.
2. Entrusted third parties to complete full REACH-SVHC screening and RoHS hazardous substance testing, issuing compliance DoC statements exclusively for Japanese import raw material filing.
3. Precisely determined HS codes and completed export commodity inspection and pharmaceutical raw material export pre-review in advance.
After full inspection and qualification of all 18 tons of customized L-theanine, goods were loaded at Shanghai Port for sea transport to Osaka Port, Japan. Complete pharmacopoeia reports and compliance documents were submitted to Japan Ministry of Health for entry inspection, enabling one-time customs clearance and direct delivery to the client’s GMP formulation factory for mass production of health food and pharmaceutical auxiliary materials. All finished product indicators matched original fermented raw materials, reducing the client’s comprehensive raw material procurement cost by 32.1%.
After 6 months of mass production verification, product defect rates and formulation stability matched imported raw materials. The client immediately signed an annual framework procurement contract for 128 tons of customized L-theanine with balanced monthly delivery batches. Subsequent customized domestic production and compliant import of multiple pharmaceutical amino acids including γ-aminobutyric acid and valine were fully entrusted to HiSiaddi for overall coordination.
HiSiaddi built independent product archives for HEALTHLIFE, storing customized production processes, full pharmacopoeia batch test reports and compliance filing documents for every batch. Annual follow-ups on updates to Japanese JP Pharmacopoeia editions and REACH-SVHC list revisions are conducted to synchronously update product testing and compliance documents. Clients may apply for free customized samples during new formula R&D to shorten new product launch cycles.
1. Natural technical gap between domestic food-grade mass production processes and Japanese pharmaceutical-grade customization requirements: The vast majority of domestic L-theanine manufacturers focus on the national standard food additive market, with equipment, cleanliness and refining processes designed for 98% purity national standards. They lack capabilities for pharmaceutical-grade deep purification and Class D clean workshop support, and are unwilling to conduct technical transformation for small-batch high-end customization – a common pain point restricting domestic substitution of pharmaceutical amino acids into high-end Japanese and South Korean pharmaceutical supply chains.
2. Distinct procurement logic for mid-to-high-end Japanese and South Korean pharmaceutical raw materials compared with low-volume retail buyers: Low-end purchasers only prioritize spot prices and lead times, while Japanese pharmaceutical end buyers prioritize pharmacopoeia-grade indicators, refined control of chirality and impurities, full-chain multi-country compliance and GMP-compliant production environments. Minor indicator non-compliance will block Ministry of Health entry filing and prevent pharmaceutical production.
3. HiSiaddi’s differentiated core competitiveness: Integrated customized amino acid R&D, production coordination and cross-border compliance capabilities. Breaking the traditional foreign trade spot resale model, we leverage raw material technology and GMP factory resources to connect the full chain from small-batch R&D to customized exports, resolving the dual pain points of factories refusing technical transformation for small orders and overseas pharmaceutical enterprises struggling to source compliant customized raw materials. Long-term stable repeat orders are secured through customized technical support.
Contact HiSiaddi customer service for more customized service requirements.
+86-13120989737 
info@hisiaddi.com 
English
